{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T04:37:22Z","timestamp":1774413442855,"version":"3.50.1"},"reference-count":20,"publisher":"Hindawi Limited","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2130,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1111\/j.1365-2354.2008.00980.x","type":"journal-article","created":{"date-parts":[[2009,6,22]],"date-time":"2009-06-22T09:55:26Z","timestamp":1245664526000},"page":"653-656","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer"],"prefix":"10.1155","volume":"18","author":[{"given":"P.","family":"HERAS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"KRITIKOS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"HATZOPOULOS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-P.","family":"GEORGOPOULOU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","reference":[{"issue":"1","key":"10.1111\/j.1365-2354.2008.00980.x-BIB1","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S8756-3282(09)80011-2","article-title":"Metastatic bone disease: clinical and therapeutic aspects","volume":"13","author":"Body","year":"1992","journal-title":"Bone"},{"key":"10.1111\/j.1365-2354.2008.00980.x-BIB2","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","article-title":"Current use of bisphosphonates in oncology. International Bone and Cancer Study Group","volume":"16","author":"Body","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2354.2008.00980.x-BIB4","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandrone reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Annals of Oncology"},{"key":"10.1111\/j.1365-2354.2008.00980.x-BIB3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"10.1111\/j.1365-2354.2008.00980.x-BIB5","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomized, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"British Journal of Cancer"},{"key":"10.1111\/j.1365-2354.2008.00980.x-BIB6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/bjc.1997.66","article-title":"Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy","volume":"75","author":"Body","year":"1997","journal-title":"British Journal of Cancer"},{"issue":"8","key":"10.1111\/j.1365-2354.2008.00980.x-BIB7","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1111\/j.1365-2354.2008.00980.x-BIB8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treatment Reviews"},{"key":"10.1111\/j.1365-2354.2008.00980.x-BIB9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"British Journal of Cancer"},{"key":"10.1111\/j.1365-2354.2008.00980.x-BIB10","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/bjc.1998.52","article-title":"Clinical course and prognostic factors following bone recurrence from breast cancer","volume":"77","author":"Coleman","year":"1998","journal-title":"British Journal of Cancer"},{"key":"10.1111\/j.1365-2354.2008.00980.x-BIB12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3816\/CBC.2000.n.003","article-title":"Treatment of metastatic bone disease in breast cancer: bisphosphonates","volume":"1","author":"Diel","year":"2000","journal-title":"Clinical Breast Cancer"},{"key":"10.1111\/j.1365-2354.2008.00980.x-BIB11","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2004.03.025","article-title":"Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer","volume":"40","author":"Diel","year":"2004","journal-title":"European Journal of Cancer"},{"key":"10.1111\/j.1365-2354.2008.00980.x-BIB13","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2354.2008.00980.x-BIB14","first-page":"CD003474","article-title":"Bisphosphonate for breast cancer","volume":"1","author":"Pavlakis","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1111\/j.1365-2354.2008.00980.x-BIB16","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer Journal"},{"key":"10.1111\/j.1365-2354.2008.00980.x-BIB15","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1111\/j.1365-2354.2008.00980.x-BIB17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1023\/A:1006308619659","article-title":"Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis","volume":"59","author":"Solomayer","year":"2000","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1111\/j.1365-2354.2008.00980.x-BIB18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00001813-199210000-00002","article-title":"Bone metastasis in breast cancer","volume":"3","author":"Theriault","year":"1992","journal-title":"Anticancer Drugs"},{"key":"10.1111\/j.1365-2354.2008.00980.x-BIB19","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1111\/j.1365-2354.2008.00980.x-BIB20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/j.seminoncol.2004.07.025","article-title":"Ibandronate reduces skeletal morbidity in patients with breast cancer","volume":"31","author":"Tripathy","year":"2004","journal-title":"Seminars in Oncology"}],"container-title":["European Journal of Cancer Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2354.2008.00980.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2354.2008.00980.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:09:35Z","timestamp":1671541775000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2354.2008.00980.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2354.2008.00980.x","relation":{},"ISSN":["0961-5423","1365-2354"],"issn-type":[{"value":"0961-5423","type":"print"},{"value":"1365-2354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}